That could have serious implications for patients .Last month , the F. D. A. released a study of 22 drugs that appeared promising in early studies but failed in final ,    trials .Drug safety watchdogs point to examples like the painkiller Vioxx , which was withdrawn from the market in 2004 over safety concerns , as proof of the high stakes involved in drug approval .While Mr. Trump â€™s call to cut regulations has been warmly received by other industries , some biotech executives have reacted to his remarks with alarm .